Yi-chen Zhang
106 Zhongshan 2nd Road
Guangzhou, 510080, China
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Optimizing First-Line Combination Treatment for EGFR-Mutated NSCLC: Does One Size Fit All?
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 08, 2026
The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: December 13, 2025
Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 03, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study.
Journal: Biomarker research
Published: May 24, 2025
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma.
Journal: Oncoimmunology
Published: April 11, 2024
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
Journal: Journal of translational medicine
Published: February 04, 2024
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study.
Journal: Therapeutic advances in medical oncology
Published: July 05, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 03, 2023
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer.
Journal: Molecular carcinogenesis
Published: February 08, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Journal: Molecular oncology
Published: December 14, 2022
Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
Journal: Journal of cancer research and clinical oncology
Published: May 30, 2022
Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.
Journal: Frontiers in oncology
Published: December 16, 2021
Last Updated: 09/26/2026